Levin Johannes, Hasan Alkomiet, Höglinger Günter U
Department of Neurology, Ludwig-Maximilians-Universität, Munich, Germany.
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany.
J Neural Transm (Vienna). 2016 Jan;123(1):45-50. doi: 10.1007/s00702-015-1400-x. Epub 2015 Apr 18.
Psychosis in Parkinson's disease (PD) is a frequent condition affecting >20 % of all PD patients. It is characterized by vivid dreams, nightmares, illusions, delusions and mostly visual hallucinations. Typically psychosis occurs in the late stage of PD, affecting up to 70 % of the patients following a disease duration of 20 years or more, and can severely interfere with the care of the patients, especially if the patients develop delusions. Psychosis is the principal cause of admission to a nursing home for PD patients. Hence, preemptive identification of risk factors, and avoidance and elimination of triggers are most important measures against psychosis in PD patients. Secondarily, pharmaceutical measures are being undertaken successively, including simplification of medication regimes, discontinuation of non-essential CNS-active drugs, ordered reduction of antiparkinsonian drugs, addition of cholesterinase inhibitors in cognitively impaired patients, and finally addition of antipsychotic medication with limited parkinsonian side effects. As psychosis in PD is a frequent and important problem, we set out to write a state-of-the-art guideline for its identification and treatment.
帕金森病(PD)中的精神病是一种常见病症,影响超过20%的所有PD患者。其特征为生动的梦境、噩梦、幻觉、妄想,且大多为视幻觉。典型的精神病发生在PD的晚期,在疾病持续20年或更长时间后,高达70%的患者会受到影响,并且会严重干扰患者的护理,尤其是当患者出现妄想时。精神病是PD患者入住疗养院的主要原因。因此,预先识别风险因素以及避免和消除诱因是预防PD患者发生精神病的最重要措施。其次,正在相继采取药物措施,包括简化用药方案、停用非必要的中枢神经系统活性药物、有序减少抗帕金森病药物、在认知受损患者中添加胆碱酯酶抑制剂,最后添加帕金森病副作用有限的抗精神病药物。由于PD中的精神病是一个常见且重要的问题,我们着手编写一份关于其识别和治疗的最新指南。